State Key Laboratory of Cell Biology, CAS Center for Excellence on Molecular Cell Science, Innovation Center for Cell Signaling Network, Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, 200031, P. R. China.
University of Chinese Academy of Sciences, Beijing, 100049, P. R. China.
Cancer Commun (Lond). 2019 Oct 1;39(1):53. doi: 10.1186/s40880-019-0402-8.
Despite the tremendous efforts for improving therapeutics of lung cancer patients, its prognosis remains disappointing. This can be largely attributed to the lack of comprehensive understanding of drug resistance leading to insufficient development of effective therapeutics in clinic. Based on the current progresses of lung cancer research, we classify drug resistance mechanisms into three different levels: molecular, cellular and pathological level. All these three levels have significantly contributed to the acquisition and evolution of drug resistance in clinic. Our understanding on drug resistance mechanisms has begun to change the way of clinical practice and improve patient prognosis. In this review, we focus on discussing the pathological changes linking to drug resistance as this has been largely overlooked in the past decades.
尽管为改善肺癌患者的治疗效果做出了巨大努力，但预后仍然令人失望。这在很大程度上归因于对耐药性缺乏全面了解，导致临床上缺乏有效的治疗方法。基于目前肺癌研究的进展，我们将耐药机制分为分子、细胞和病理三个不同水平。所有这三个水平都对临床耐药性的获得和演变做出了重要贡献。我们对耐药机制的认识已经开始改变临床实践的方式，改善患者的预后。在这篇综述中，我们重点讨论与耐药性相关的病理变化，因为在过去几十年中，这方面一直被忽视。
Zotero 插件
